MINIMALLY INVASIVE METHOD FOR DIAGNOSING NON-ALCOHOLIC FATTY LIVER DISEASE BASED ON THE IDENTIFICATION OF MIRNAS AND MIP-1β IN BLOOD PLASMA Russian patent published in 2023 - IPC G01N33/58 G01N33/68 G01N33/543 C12Q1/6806 C12Q1/686 C12Q1/6876 

FIELD: medicine; medical genetics.

SUBSTANCE: invention can be used for minimally invasive diagnosis of non-alcoholic fatty liver disease (NAFLD) in obese patients. The miR-423-5p and let-7a-5p microRNA expression levels are analyzed by real-time PCR and MIP-1 concentrationsβ enzyme immunoassay in the blood plasma of obese patients. To calculate the NAFLD coefficient, the obtained data are substituted into the calculation formula. If the coefficient of NAFLD is 6.8 or higher, the presence of NAFLD is diagnosed in obese patients, if the coefficient is less than 6.8, the absence of NAFLD is diagnosed.

EFFECT: method enables minimally invasive diagnosis of NAFLD in obese patients by using the formula for calculating the NAFLD coefficient based on the values of miR-423-5p and let-7a-5p expression levels and MIP-1 concentrationβ in blood plasma.

1 cl, 2 ex